Provention Bio Closes Upsized IPO

7/19/18

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public offering of shares of its common stock at a public offering price of $4.00 per share on July 19, 2018. The gross proceeds from the offering were approximately $63.9 million, before deducting underwriting discounts and commissions and other offering expenses. Shares of the Company's common stock are expected to begin trading on The Nasdaq Capital Market under the ticker symbol "PRVB" on Tuesday, July 24, 2018.

MDB Capital Group, LLC acted as sole book-running manager for the offering. Dougherty & Company LLC acted as qualified independent underwriter for the offering.

About Provention Bio, Inc.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Our diverse portfolio was assembled with product candidates that have undergone clinical testing but may have been underdeveloped or deprioritized assets at other companies. Provention's mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, lupus, and certain life-threating viral diseases. For more information on Provention Bio, please visit www.proventionbio.com.

About MDB Capital Group

MDB Capital Group sponsors scientists and entrepreneurs that possess meaningful technology which has the potential to impact significant commercial markets and benefit humanity. MDB maximizes the probability of commercialization by positioning companies as a leader in their technology domain, connecting them with a community of high quality investors and bringing the companies public during the development phase. For more information, visit www.mdb.com